301医院 郭明洲教授

郭明洲, 2007 年 5 月至今被聘为中 国人民解放军总医院消化科研究员。主要从事肿瘤表 观遗传学（Epigenetics）方面的研究，特别是消化系统肿瘤的表观遗传学研究。 在等国际学术期刊已发表论文（SCI）60 余篇。 主编中文专著一部，编写英文章节的专著两部。申请专利 3 项。目前承担 973、863、国家重点科学仪器专项、国家自然科学基金面上项目、国家自然科 学基金创新群体基金、国家自然科学基金中美合作基金等项目。 2005 年至今被聘为郑州大学特聘教授。 1999 年 1 月2006.6 在美国约翰霍普金斯大学肿瘤中心从事博士后研究工作。 1998 月 7 月毕业于同济医科大学医学系 消化专业获医学博士学位 。 1992 年 7 月毕业于河南医科大学医学系消化专业获医学硕士学位。 博士, 1986 月 7 月 毕业于河南医科大学临床医学系获医学学士学位。 姓名： 郭明洲 出生年月：1962 年 9 月 1 日 婚史：已婚 现工作单位及联系方式： 中国人民解放军总医院消化科 北京市海淀区复兴路号 电话： 86-10-66937651，手机) 传真: 86-10-68180325 现职位：研究员，教授 从事专业：消化系病，分子肿瘤学 学历与研究经历： 学士 1981 月 9 月- 1986 月 6 月 河南医科大学 郑州 450052 硕士 1989 月 9 月- 1992 月 6 月 河南医科大学第二附属医院消化内科 郑州 450052 博士 1995 年 9 月- 1998 年 6 月 同济医科大学协和医院消化科 武汉 430022 博士后 1998 年 12 月2006.4 美国约翰霍普金斯大学肿瘤中心 工作经历： 1986 年 7 月-1989 年 8 月 河南省郑州市二院 住院医生 郑州 450000 1992 月 6 月- 1995 月 8 月 河南医科大学消化研究所，河南医科大学二附院 消化内科 主治医师，讲师 郑州 450053 2005-至今： 郑州大学 教授 2006 年-2008 年 美国约翰霍普金斯大学肿瘤中心 副研究员 2008 年至今：中国人民解放军总医院 研究员，教授 学术兼职 1992 年 6 月 -2005 胃肠病学和肝病学杂志 编辑、编辑部主任 2005 年2007 胃肠病学和肝病学杂志 常务副主编 2007- 至今 胃肠病学和肝病学杂志 共同主编 2012 年-2016 年 胃肠病学 编委 2011 年-2014 年 中华消化协会肿瘤学组 委员 2012 年-2014 年 中国抗癌协会肿瘤纳米学会 委员 主要研究方向 ：肿瘤表观遗传学 长期从事肿瘤的分子诊断及发病机制的研究，特别是在肿瘤表观遗传学方面具 有一定的研究积累，对食管癌等消化道肿瘤进行了大量研究。 目前承担以下课题： 1. 功能纳米材料与肿瘤细胞外基质的相互作用对肿瘤恶性表型调控作用研 究 （973） 2012CB934002 （310 万） 2. 肿瘤非编码 RNA 转录加工相关蛋白的功能研究 (973) 2010CB912802（550 万） （课题负责人） 3. 食管癌的“基因-环境互作 ”“组学”研究 SS2012AA020314 （863）（100 万） 4. 食管癌中 DNA 甲基化、组蛋白修饰和 miRNA 对 Sox17 的转录调控（国家自 然科学基金面上项目） 81071953（38 万）（课题负责人） 5. 平行研究在大鼠和人食管癌前病变中 MAPK,NFkB 和氧化应激通路的作用 （国家自然科学基金面上项目中美合作基金） 81161120432（30 万）（课题负 责人） 6. 肿瘤微环境细胞的高通量分选、高效率转染及无标记检测系统平台（国家科 学仪器重大专项） 2011YQ03013405 （188 万）（课题负责人） 7. 胃癌分子分型和个体化诊疗技术（863） SS2012AA020821 （100 万） 8. 胃癌的“组学“整合研究（863）SS2012AA020303 （100 万） 9. 严重创伤机体重要组织和器官损伤修复与再生研究（国家自然科学基金创新 群体基金） 81121004 （80 万） Peer review papers（发表的英文论文） 1. Liu X, Zhang X, Zhan Q, Brock M, Herman JG, Guo M. CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. Cancer Biol Ther. 2012 Oct 1;13(12). Epub ahead of print (correspondence) 2. Yin D, Jia Y, Yu Y, Brock MV, Herman JG, Han C, Su X, Liu Y, Guo M. SOX17 methylation inhibits its antagonism of Wnt signaling pathway in lung cancer. Discov Med. 2012 Jul;14(74):33-40. (correspondence) 3. Jia Y, Yang Y, Brock MV, Zhan Q, Herman JG, Guo M. Epigenetic Regulation of DACT2, A Key Component of the Wnt Signaling Pathway in Human Lung Cancer. J Pathol. 2012 Jul 18. doi: 10.1002/path.4073. Epub ahead of print (correspondence) 4. Yan Jia,Yunsheng Yang, Qimin Zhan, Hongbin Zhu, Yuanzi Yu, James G. Herman and Mingzhou GuoMicroRNA-141 and Methylation Regulation of WNT Signal Pathway by Suppressing SOX17 in Esophageal Cancer. Journal of Molecular Diagnosis. 14 (6): 2012. (In Press) (correspondence) 5. Yan WJ, Guo MZ, Yang YS. The role of hypermethylation in promoter region of ubiquitin carboxyl-terminal hydrolase L1 in human esophageal cancer. Zhonghua Nei Ke Za Zhi. 2012 May;51(5):390-3. 6. Chen T, Yan F, Qian J, Guo M, Zhang H, Tang X, Chen F, Stoner GD, Wang X. Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. Cancer Prev Res (Phila). 2012 Jan;5(1):41-50. Epub 2011 Dec 1. 7. Ning B, Liu G, Liu Y, Su X, Anderson GJ, Zheng X, Chang Y, Guo M, Liu Y, Zhao Y, Nie G. 5-aza-2-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. J Biol Chem. 2011 Oct 28;286(43):37196-206. Epub 2011 Sep 7. 8. Chen YH, Wu ZQ, Zhao YL, Si YL, Guo MZ, Han WD. FHL2 inhibits the Id3- promoted proliferation and invasive growth of human MCF-7 breast cancer cells. Chin Med J (Engl). 2012 Jul;125(13):2329-33. 9. Chen XY, He QY, Guo MZ. XAF1 is frequently methylated in human esophageal cancer. World J Gastroenterol. 2012 Jun 14;18(22):2844-9. (correspondence) 10. Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. SOX17 antagonizes WNT/beta- catenin signaling pathway in hepatocellular carcinoma. Epigenetics. 2010 Nov- Dec;5(8):743-9. Epub 2010 Nov 22. (correspondence) 11. Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, Li Y, Yu Y, Herman JG, Guo M. Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics. 2012 Apr;4(2):135-46. (correspondence) 12. Deng YZ, Yao F, Li JJ, Mao ZF, Hu PT, Long LY, Li G, Ji XD, Shi S, Guan DX, Feng YY, Cui L, Li DS, Liu Y, Du X, Guo MZ, Xu LY, Li EM, Wang HY, Xie D. RACK1 Suppresses Gastric Tumorigenesis by Stabilizing the -Catenin Destruction Complex. Gastroenterology. 2012 Apr;142(4):812-823.e15. Epub 2012 Jan 10. 13. Yu Y, Yin D, Hoque MO, Cao B, Jia Y, Yang Y, Guo M. Tumour Biol. AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. Tumour Biol. 2012 Apr;33(2):307-14 (correspondence) 14. Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer. 2011 Nov 4. doi: 10.5732/cjc.011.10245. Epub ahead of printPMID:22059907PubMed - as supplied by publisher (correspondence) 15. Xiao-Mei Zhang and Ming-Zhou Guo . The value of epigenetic markers in esophageal cancer. Front Med China 4(4):378-84 (2010) Review. (correspondence) 16. Gong Y, Yang YS, Zhang XM, Su M, Wang J, Han JD, Guo MZ. ABO blood type, diabetes and risk of gastrointestinal cancer in northern China. World J Gastroenterol. 2012 Feb 14;18(6):563-9. (correspondence) . 17. Ying Chen, Chun-min Yang, Gao-ping Mao, Qing-sen Liu and Ming-zhou Guo. Effects of simulated weightlessness on the intestinal mucosal barrier of rats. J Huazhong Univ Sci Technolog Med Sci. 2011 Feb;31(1):26-32. Epub 2011 Feb 19) 18. Hou J, Li EM, Shen JH, Qing-Zhao, Wu ZY, Xu XE, Wu JY, Qiao-Huang, Shen J, Guo MZ, Xu LY. Cytoplasmic HDPR1 is involved in regional lymph node metastasis and tumor development via beta-catenin accumulation in esophageal squamous cell carcinoma. J Histochem Cytochem. 2011 Jul;59(7):711-8. Epub 2011 Apr 27. (Co-correspondence). 19. Wang J, Zhao W, Cheng L, Guo M, Li D, Li X, Tan Y, Ma S, Li S, Yang Y, Chen L, Wang S. CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice. J Immunol. 2010 Dec 15;185(12):7654-62. Epub 2010 Nov 8. 20. Ye Zhao, Jian-Sheng Li, Ming-Zhou Guo, Bai-Sui Feng and Jin-Ping Zhang Inhibitory effect of S-adenosylmethionine on the growth of human gastric cancer cells in vivo and in vitro. Chin J Cancer 29(8):752-60 21. Wang M, Cheng Z, Tian T, Chen J, Dou F, Guo M, Cong YS. Differential expression of oncogenic miRNAs in proliferating and senescent human fibroblasts. Mol Cell Biochem. 2011 Mar 17. Epub ahead of print 22. Zhao Y, Li JS, Guo MZ, Feng BS, Zhang JP, Chen XY. Effects of S- adenosylmethionine on gastric cancer cell lines SGC-7901 and BGC-823. Zhonghua Yi Xue Za Zhi. 2010 Jun 8;90(22):1559-64. 23. Zhang XL, Yang YS, Sun G, Guo MZ. Natural orifice translumenal endoscopic surgery (NOTES): current status and challenges.Chin Med J (Engl). 2010 Jan 20;123(2):244-7. Review 24. Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics. 2008 Nov;3(6):336-41. Epub 2008 Nov 8. 25. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, Liu Z, Rustgi AK, Herman JG. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer. 2007 Sep 15;121(6):1219-26. 26. Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med. 2006 May 18;354(20):2193-4. 27. Guo M, House MG, Akiyama Y, Qi Y, Capagna D, Harmon J, Baylin SB, Brock MV, Herman JG. Hypermethylation of the GATA gene family in esophageal cancer. Int J Cancer. 2006 Jul 5;119(9):2078-2083 28. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006 Aug 1;12(15):4515-22. 29. Guo M, House MG, Hooker C, Han Y, Heath E, Gabrielson E, Yang SC, Baylin SB, Herman JG, Brock MV. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res. 10: 5131-5136, 2004. 30. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res. 10:7917-7924, 2004. 31. Guo M, Liu S, Herman, JG, Zhuang, H Lu, F. Gefitinib-Sensitizing Mutation in Esophageal Carcinoma Cell Line Kyse450. Cancer Biol Ther. 2006 Feb;5(2):152-5. 32. Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, Wang S, Herman JG, Canto MI. DNA Promoter Hypermethylation of p16 and APC Predicts Neoplastic Progression in Barretts Esophagus. Am J Gastroenterol. 2009 Jul 7. Epub ahead of print 33. Ye Y, McDevitt MA, Guo M, Zhang W, Galm O, Gore SD, Karp JE, Maciejewski JP, Kowalski J, Tsai HL, Gondek LP, Tsai HC, Wang X, Hooker C, Smith BD, Carraway HE, Herman JG. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res. 2009 Nov 1;69(21):8482-90. Epub 2009 Oct 13. 34. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol. 163:1101-1107, 2003. ( first author equal contribution) 35. Riojas MA, Guo M, Glckner SC, Machida EO, Baylin SB, Ahuja N. Methylation- Induced Silencing of ASC/TMS1, a Pro-Apoptotic Gene, is a Late-Stage Event in Colorectal Cancer. Cancer Biol Ther. 2007 Nov;6(11):1710-6. Epub 2007 Aug 3. ( first author equal contribution) 36. Fu B, Guo M, Wang S, Campagna D, Luo M, Herman JG, Iacobuzio-Donahue CA. Evaluation of GATA-4 and GATA-5 Methylation Profiles in Human Pancreatic Cancers Indicate Promoter Methylation Patterns Distinct from other Human Tumor Types. Cancer Biol Ther. 2007 Oct;6(10):1546-52. 37. Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Galm O, Baylin SB, Herman JG. Hypermethylation associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res. 6 :5902-5905, 2002. 38. House MG, Guo M, Efron DT, Lillemoe KD, Cameron JL, Syphard JE, Hooker CM, Abraham SC, Montgomery EA, Herman JG, Brock MV. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg. 7:1004-1014, 2003. 39. Brock MV, Gou M, Akiyama Y, Muller A, Wu TT, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller RF, Yang SC, Forastiere AA, Baylin SB, Herman JG. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 9:2912-2919, 2003. 40. House MG, Guo M, Iacobuzio-Donahue C, Herman JG. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 24:193-198, 2003. 41. Zhang W, Glckner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, Ahuja N, Baylin SB. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008 Apr 15;68(8):2764-72. 42. Carraway HE, Wang S, Blackford A, Guo M, Powers P, Jeter S, Davidson NE, Argani P, Terrell K, Herman JG, Lange JR. Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Res Treat. 2008 Apr 11. Epub ahead of print 43. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008 Mar 13;358(11):1118-28. 44. Liu ZM, Ding F, Guo MZ, Zhang LY, Wu M, Liu ZH. Down regulation of retinoic acid receptor-beta(2) expression is linked to aberrant methylation in esophageal squamous cell carcinoma cell lines. World J Gastroenterol. 10:771-775, 2004. 45. Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, Klein PS, Rustgi A, Diehl JA. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene. 2006 Oct 12;25(47):6291-303. Epub ahead of print 46. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet.10:3001-3007, 2001. 47. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery. 134:902-908, 2003. 48. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, Cameron JL, Hruban RH, Maitra A, Yeo CJ. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 238:423-431, 2003. 49. Hong KM, Yang SH, Guo M, Herman JG, Jen J. Semiautomatic detection of DNA methylation at CpG islands. Biotechniques. 38:354-358, 2005. 50. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 18:412-420, 2005. 51. House MG, Wistuba II, Argani P, Guo M, Schulick RD, Hruban RH, Herman JG, Maitra A. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol. 10:882-889, 2003. 52. Lu F, Chen H, Zhou C, Liu S, Guo M, Chen P, Zhuang H, Xie D, Wu S. T-type Ca(2+) channel expression in human esophageal carcinomas: A functional role in proliferation. Cell Calcium. 2008 Jan;43(1):49-58. Epub 2007 May 25. 53. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, Siegfried JM, Yu J, Zhang L. Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation. Clin Cancer Res 2007 Aug 1;13(15 Pt 1):4336-44. 54. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63:1114-1121, 2003. 55. Liu ZM, Zhang L, Ding F, Li J, Guo M, Li W, Wang Y, Yu Z, Zhan Q, Wu M, Liu Z. 5-Aza-2-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells. Cancer Lett. 230:271-283, 2005. 56. Brock MV, Hooker CM, Yung R, Guo M, Han Y, Ames SE, Chang D, Yang SC, Mason D, Sussman M, Baylin SB, Herman JG. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis? Ann Thorac Surg. 80:1241-1247, 2005. 57. Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, Zhang W, Guo M, Curran J, Han S, Sidransky D, Buetow K, Madden SL, Jen J. Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A. 18:15203-15208, 2001. 58. Moreno-Bueno G, Hardi